MYCN and neuroblastoma: AMXT1501 is one such inhibitor that in combination with DFMO has been shown to have anti-tumor and immune stimulatory activities in a mouse model of squamous cell carcinoma [72,73] and also to inhibit neuroblastoma proliferation in vitro [69] and extend survival of TH-MYCN mice with neuroblastoma in vivo.